Seminars in Hematology

Papers
(The TQCC of Seminars in Hematology is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Special issue on chronic lymphocytic leukemia: Prognostication and therapeutic options introductory editorial140
CAR T-cell therapy comes of age: Introductory editorial for the special issue60
Clinical applications of circulating tumor DNA in Hodgkin lymphoma40
Extramedullary myeloma in the era of CAR T-cell and bispecific antibody therapies33
Insights from the 12th International Workshop on Waldenstrom's Macroglobulinemia31
Evolving Insights into Mitochondrial Presence in RBC in Sickle Cell Disease: Red Blood Cell and Reticulocyte Pathophysiology, Therapeutic Strategies, and Future Directions29
Clonality in immune aplastic anemia: Mechanisms of immune escape or malignant transformation28
Updates on current and future research in acute myeloid leukemia27
The winding road: Infectious disease considerations for CAR-T and other novel adoptive cellular therapies in the era of COVID-1922
How to set up a clinical research center in Brazil, as an example of a middle-income country21
Epidemiology and etiology of diffuse large B-cell lymphoma20
Lessons learned from the Eµ-TCL1 mouse model of CLL19
Somatic mutations in “benign” blood diseases19
Immune-driven clonal cell selection at the intersection among cancer, infections, autoimmunity and senescence18
The future of lymphoma diagnosis, prognosis, and treatment monitoring in countries with limited access to pathology services17
Antibody and immunotherapy in diffuse large B-cell lymphoma17
More disease-modifying therapies for sickle cell disease: Are small molecules and drug repurposing the way forward?16
TET2 mutation as prototypic clonal hematopoiesis lesion16
Intestinal microbiome and myelodysplastic syndromes: Current state of knowledge and perspectives for future15
MRD-driven treatment strategies in CLL: Current practice, limitations, and emerging paradigms15
The role of viruses in HIV-associated lymphomas15
Accelerating accessibility of CAR-T/NK therapies – Are AlloCARs and rapid manufacturing platforms the road ahead in improving access in multiple myeloma?14
The molecular map of CLL and Richter's syndrome13
T-cell engaging antibodies for B-cell lymphomas13
Report of Consensus Panel 5 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors13
Developing MRD as an early endpoint for accelerated approval in CLL12
Roadmap for developing MRD as an early endpoint for drug approval in lymphoma12
At the cusp of a cure in Myeloma: Insights into pathogenesis, modeling and therapeutics12
Vaccinations in patients with chronic lymphocytic leukemia12
Role of MRD testing in acute myeloid leukemias. What is the status and how to get there?11
Clonal hematopoiesis11
Cellular and immunotherapies for myelodysplastic syndromes11
outside front cover, PMS 8883 metallic AND 4/C11
Challenges and opportunities of CAR T-cell therapies for CLL10
outside front cover, PMS 8883 metallic AND 4/C10
Advancements in bispecific antibodies for multiple myeloma: What's new and what lies ahead10
B-cell receptor immunoglobulin stereotypy in chronic lymphocytic leukemia: Key to understanding disease biology and stratifying patients10
Harnessing single-domain antibodies for CAR-T and bispecific antibody development9
The biology of classical Hodgkin lymphoma9
Access to essential therapy for sickle cell disease in Africa: Experience from a national program in Ghana9
Management of Myelodysplastic Syndrome in Pregnant Patients: Treatment Approaches and Considerations9
Mobilizing CARs: Benefits, drawbacks, and directions for outpatient CAR T-cell therapy9
Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia9
Menin inhibition for the treatment of acute leukemia8
Engineering the Next Generation of Antibody Therapeutics in Hematology8
A tower of babel of acronyms? The shadowlands of MGUS/MBL/CHIP/TCUS8
Somatic mutations in acquired pure red cell aplasia8
The pediatric approach to Hodgkin lymphoma8
Clinical applications of circulating tumor DNA in central nervous system lymphoma7
The spectrum of somatic mutations in large granular lymphocyte leukemia, rheumatoid arthritis, and Felty's syndrome7
Report of Consensus Panel 2 from the 12th International Workshop on the management of Bing-Neel syndrome in patients with Waldenstrom’s Macroglobulinemia7
DLBCL arising from indolent lymphomas: How are they different?7
Understanding MDS stem cells: Advances and limitations7
The crossroads of cancer therapies and clonal hematopoiesis7
MRD as an early endpoint in myeloma and other hematologic malignancies: Implication for ongoing and future study designs7
Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials7
Blood-based MRD testing in multiple myeloma: Update on mass spectrometry methods for detecting the monoclonal immunoglobulin7
Somatic compensation of inherited bone marrow failure7
The emergence of a new paradigm with signal 1 and signal 2 T-cell engagers in hematology7
0.037386894226074